JP6170675B2 - 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 - Google Patents

受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 Download PDF

Info

Publication number
JP6170675B2
JP6170675B2 JP2012551318A JP2012551318A JP6170675B2 JP 6170675 B2 JP6170675 B2 JP 6170675B2 JP 2012551318 A JP2012551318 A JP 2012551318A JP 2012551318 A JP2012551318 A JP 2012551318A JP 6170675 B2 JP6170675 B2 JP 6170675B2
Authority
JP
Japan
Prior art keywords
peptide
rap
fucosidase
complex
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012551318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518128A5 (https=
JP2013518128A (ja
Inventor
トッド シー． ザンケル，
トッド シー． ザンケル，
Original Assignee
ラプトール ファーマシューティカルズ インコーポレイテッド
ラプトール ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラプトール ファーマシューティカルズ インコーポレイテッド, ラプトール ファーマシューティカルズ インコーポレイテッド filed Critical ラプトール ファーマシューティカルズ インコーポレイテッド
Publication of JP2013518128A publication Critical patent/JP2013518128A/ja
Publication of JP2013518128A5 publication Critical patent/JP2013518128A5/ja
Application granted granted Critical
Publication of JP6170675B2 publication Critical patent/JP6170675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012551318A 2010-01-28 2011-01-28 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法 Expired - Fee Related JP6170675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29917710P 2010-01-28 2010-01-28
US61/299,177 2010-01-28
PCT/US2011/022917 WO2011094536A1 (en) 2010-01-28 2011-01-28 Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016043181A Division JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Publications (3)

Publication Number Publication Date
JP2013518128A JP2013518128A (ja) 2013-05-20
JP2013518128A5 JP2013518128A5 (https=) 2014-02-20
JP6170675B2 true JP6170675B2 (ja) 2017-07-26

Family

ID=44319804

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012551318A Expired - Fee Related JP6170675B2 (ja) 2010-01-28 2011-01-28 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
JP2016043181A Pending JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016043181A Pending JP2016145231A (ja) 2010-01-28 2016-03-07 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法

Country Status (10)

Country Link
US (1) US20110189084A1 (https=)
EP (1) EP2528613B1 (https=)
JP (2) JP6170675B2 (https=)
KR (1) KR101784539B1 (https=)
CN (1) CN102905716B (https=)
AU (1) AU2011210756B2 (https=)
CA (1) CA2788175A1 (https=)
ES (1) ES2555555T3 (https=)
TW (1) TWI558397B (https=)
WO (1) WO2011094536A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
RU2474423C1 (ru) * 2011-12-20 2013-02-10 Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) Способ лечения метастазов печени
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
JP6981961B2 (ja) * 2015-07-30 2021-12-17 ホライズン オルファン エルエルシー フコシダーゼ阻害剤
EP3966199B1 (en) * 2019-05-10 2026-03-18 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5153325A (en) * 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5096909A (en) * 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
NZ237734A (en) * 1990-04-12 1993-05-26 Merrell Dow Pharma Cyclopentylamines, their preparation and medicaments thereof
US5240707A (en) * 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2302697T3 (es) * 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
ATE429233T1 (de) * 2001-06-29 2009-05-15 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
US6852842B2 (en) 2002-08-26 2005-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for functional kidney imaging using small dendrimer contrast agents
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) * 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2009506136A (ja) * 2005-07-18 2009-02-12 ザ スクリプス リサーチ インスティテュート 両親媒性デンドリマーの製法
US8188563B2 (en) 2006-07-21 2012-05-29 The Regents Of The University Of California Shallow-trench-isolation (STI)-bounded single-photon CMOS photodetector
EP2063905B1 (en) * 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20080116171A1 (en) * 2006-11-22 2008-05-22 Clarkson University Method For The Preferential Polishing Of Silicon Nitride Versus Silicon Oxide
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
WO2009075836A2 (en) * 2007-12-10 2009-06-18 The Brigham And Women's Hospital, Inc. Rap variants for drug delivery
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates

Also Published As

Publication number Publication date
KR20130025866A (ko) 2013-03-12
JP2016145231A (ja) 2016-08-12
TW201132343A (en) 2011-10-01
AU2011210756B2 (en) 2016-11-03
US20110189084A1 (en) 2011-08-04
AU2011210756A1 (en) 2012-08-16
EP2528613A1 (en) 2012-12-05
ES2555555T3 (es) 2016-01-04
JP2013518128A (ja) 2013-05-20
TWI558397B (zh) 2016-11-21
EP2528613B1 (en) 2015-10-21
HK1181642A1 (zh) 2013-11-15
WO2011094536A1 (en) 2011-08-04
CN102905716A (zh) 2013-01-30
CN102905716B (zh) 2016-06-01
EP2528613A4 (en) 2013-06-05
KR101784539B1 (ko) 2017-10-11
CA2788175A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
EP2063905B1 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
JP2010503710A5 (https=)
EP3967755B1 (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
JP2016145231A (ja) 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
JP6981961B2 (ja) フコシダーゼ阻害剤
US20140171365A1 (en) Pegylated human hdl particle and process for production thereof
US20150353930A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
KR102387320B1 (ko) 약물 반응성 예측을 위한 대장암 진단 또는 검출용 조성물, 대장암 예방 또는 치료용 조성물
HK1181642B (en) Method for treating liver disorders with receptor associated protein ( rap) peptide-fucosidase inhibitor conjugates
EP4005583A1 (en) Cp2c-targeting peptide-based anticancer agent
US20230084893A1 (en) METHODS OF TREATING CLEAR CELL RENAL CELL CARCINOMA (ccRCC) USING AXL DECOY RECEPTORS
WO2010141097A2 (en) Pegylated human apoa-1 and process for production thereof
IL323919A (en) Administration of a beta-catenin antagonist and methods of use
HK40116513A (en) Methods of treating tissue calcification
HK1132930B (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
Lieber A Combination Therapy of JO-I and Chemotherapy in Ovarian Cancer Models
HK40070846B (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20160422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160422

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170703

R150 Certificate of patent or registration of utility model

Ref document number: 6170675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees